NFE2L2 and diabetes mellitus: After 12 weeks of oral for 1, 10, and 20 mg/kg/d in diabetes mice, andrographolide could upregulate SOD, Nrf2, HO-1, and IκB-α, as well as downregulate p65, NF-κB, TNF-α, IL-1β, IL-6, and Bax/Bc12 [71].